TEZZURA
DEAD

Serial Number

87571128

Owner

ALLERGAN SALES, LLC

Filing Date

Aug 16, 2017

Add to watchlist:

No watchlists yet
View on USPTO

TEZZURA Trademark

Serial Number: 87571128

TEZZURA is a trademark filed by ALLERGAN SALES, LLC on August 16, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN SALES, LLC (494 trademarks)

5 GIRALDA FARMS
MADISON, NJ 07940

Entity Type: 16

Trademark Details

Filing Date

August 16, 2017

Registration Date

Not Registered

Published for Opposition

March 5, 2019

Goods & Services

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceuticals and medicines for the central nervous system; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 6, 2021 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 6, 2021 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 6, 2021 EXRA
SOU EXTENSION 4 GRANTED
Apr 2, 2021 EX4G
SOU EXTENSION 4 FILED
Apr 2, 2021 EXT4
SOU TEAS EXTENSION RECEIVED
Apr 2, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 22, 2020 EXRA
SOU EXTENSION 3 GRANTED
Oct 20, 2020 EX3G
SOU EXTENSION 3 FILED
Oct 20, 2020 EXT3
SOU TEAS EXTENSION RECEIVED
Oct 20, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 31, 2020 EXRA
SOU EXTENSION 2 GRANTED
Mar 27, 2020 EX2G
SOU EXTENSION 2 FILED
Mar 27, 2020 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 27, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 26, 2019 EXRA
SOU EXTENSION 1 GRANTED
Sep 24, 2019 EX1G
SOU EXTENSION 1 FILED
Sep 24, 2019 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 24, 2019 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 30, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 5, 2019 NPUB
PUBLISHED FOR OPPOSITION
Mar 5, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 13, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 31, 2019 CNSA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 5, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jul 5, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jul 5, 2018 CNRT
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jun 6, 2018 RCCK
ASSIGNED TO LIE
Jun 5, 2018 ALIE
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 21, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 21, 2017 GNSL
SUSPENSION LETTER WRITTEN
Nov 21, 2017 CNSL
ASSIGNED TO EXAMINER
Nov 20, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 22, 2017 NWOS
NEW APPLICATION ENTERED
Aug 21, 2017 NWAP